Onkologie, Hämatologie - Daten und Informationen

Literatur zu Kapitel 6: Hochdosis-Chemotherapie

Autor/en: Stefan Knop, Hermann Einsele
Letzte Änderung: 30.06.2011
  • Alexanian R, Barlogie B, Dixon D.
    Renal failure in multiple myeloma. Pathogenesis and prognostic implications.
    Arch Intern Med 1990;150:1693-1695. PMID:2383164

  • Attal M et al.
    Intensive combined therapy for previously untreated aggressive myeloma.
    Blood 1992;79:1130-1136. PMID: 1536941

  • Attal M et al.
    A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
    N Engl J Med 1996;335:91-97. PMID:8649495

  • Attal M et al.
    Single versus double autologous stem-cell transplantation for multiple myeloma.
    N Engl J Med 2003;349:2495-2502. PMID: 14695409

  • Attal M et al.
    Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
    Blood 2006;108:3289-3294. PMID:16873668

  • Augustson BM et al.
    Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party.
    J Clin Oncol 2005;36:9219-9226. PMID:16275935

  • Avet-Loiseau H et al.
    Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
    Blood 2007;109:3489-3495. PMID:17209057

  • Badros A et al.
    Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
    Br J Haematol 2001;114:822-829. PMID:11564069

  • Barlogie B, Dicke KA, Alexanian R.
    High dose melphalan for refractory myeloma - the M.D. Anderson experience.
    Hematol Oncol 1988;6:167-172. PMID:3292374

  • Barlogie B et al.
    High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma.
    Blood 1987;70:869-872. PMID:3304465

  • Barlogie B et al.
    Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.
    Blood 1997;89:789-793. PMID:9028309

  • Barlogie B et al.
    Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
    N Engl J Med 2006;354:1021-1030. PMID:16525139

  • Barlogie B et al.
    Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
    Br J Haematol 2007;138:176-185. PMID:17593024

  • Belch A et al.
    A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
    Br J Cancer 1988;57;94-99. PMID:3279997

  • Bird JM et al.
    The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
    Br J Haematol 2006;134:385-390. PMID:16822294

  • Bladé J et al.
    Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution.
    Arch Intern Med 1998;158:1889-1893. PMID:9759684

  • Björkstrand B et al.
    Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Bone Marrow Transplant 2001;27:511-515. PMID:11313685

  • Breitkreutz I et al.
    Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield.
    Leukemia 2007;21;1294-1299. PMID:17377586

  • Case DC Jr et al.
    Phase I-II trial of high-dose melphalan in previously untreated stage III multiple myeloma: Cancer and Leukemia Group B study 8512.
    Cancer Invest 1992;10:11-17. PMID:1735010

  • Chen CI et al.
    Sequential, cycling maintenance therapy for post transplant multiple myeloma.
    Bone Marrow Transplant 2006;37:89-94. PMID:16247415

  • Cavo M et al.
    Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
    J Clin Oncol 2007;25:2434-2441. PMID:17485707

  • Chang H et al.
    Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
    Br J Haematol 2007;139:51-54. PMID:17854306

  • Child JA et al.
    High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
    N Engl J Med 2003;348:1875-1883. PMID: 12736280

  • Cunningham D et al.
    High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
    Clin Oncol 1994a;12:759-763. PMID:8151319

  • Cunningham D et al.
    High-dose melphalan for multiple myeloma: long-term follow-up data.
    J Clin Oncol 1994b;12:764-768. PMID:8151320

  • Dao DD et al.
    Deletion of the retinoblastoma gene in multiple myeloma.
    Leukemia 1994;8:1280-1284. PMID: 8057662

  • Chesi M, Kuehl WM, Bergsagel PL.
    Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma.
    Ann Oncol 2000;11 Suppl 1:131-135. PMID:10707795

  • Debes-Marun CS et al.
    Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.
    Leukemia 2003;7:427-436. PMID:12592343

  • Desikan R et al.
    Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
    Blood 2000;95:4008-4010. PMID:10845942

  • Drach J et al.
    Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance.
    Blood 1995;86:3915-3921. PMID:7579361

  • Drach J et al.
    Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
    Blood 1998;92:802-809. PMID:9680348

  • Durie BG, Salmon SE.
    A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
    Cancer 1975;36:842-854. PMID:1182674

  • Durie BG et al.
    Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.
    Blood 1990;75:823-830. PMID:2405920

  • Facon T et al.
    Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
    Blood 2001;97:1566-1571. PMID:11238092

  • Fermand JP et al.
    Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft.
    Blood 1989;73:20-23. PMID:2562921

  • Fonseca R et al.
    Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
    Leukemia 2006;20:2034-2040. PMID:17024118

  • Fonseca R et al.
    Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
    Cancer Res 2002;62:715-720. PMID:11830525

  • Fonseca R et al.
    Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
    Blood 2002;99:3735-3741. PMID:11986230

  • Gertz MA et al.
    Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement.
    Kidney Int 2005;68:1464-1471. PMID:16164623

  • Glasmacher A et al.
    A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.
    Br J Haematol 2006;132:584-593. PMID:16445831

  • Goldschmidt H et al.
    Comparison of 3 high-dose regimens with autologous peripheral blood stem transplantation for multiple myeloma: a single center experience in 261 patients.
    Proc VIIth Int Multiple Myeloma Workshop 1999;Abstract 117a.

  • Greipp PR et al.
    International staging system for multiple myeloma.
    J Clin Oncol 2005;23:3412-3420. PMID:15809451

  • Gu X, Herrera GA.
    Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia.
    Arch Pathol Lab Med 2006;130:165-169. PMID:16454555

  • Harousseau JL et al.
    Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    J Clin Oncol 2010;30:4621-4629. PMID:20823406

  • Herrera GA et al.
    Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia.
    Arch Pathol Lab Med 2004;128:875-879. PMID:15270616

  • Herrera GA.
    Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory.
    Ann Diagn Pathol 2000;4:174-200. PMID:10919389

  • Hollstein M et al.
    p53 mutations in human cancers.
    Science 1991;253:49-53. PMID:1905840

  • Horio Y et al.
    Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer.
    Cancer Res 1993;53:1-4. PMID:8380124

  • Hutchison CA et al.
    Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
    J Am Soc Nephrol 2007;18:886-895. PMID:17229909

  • Kastritis E et al.
    Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
    Haematologica 2007;92:546-549. PMID:17488666

  • Knop S et al.
    A randomized comparison of total-marrow irradiation, busulfan and cyclophosphamide with tandem high-dose melphalan in patients with newly diagnosed multiple myeloma.
    Blood (ASH Annual Meeting Abstracts) 2007 110: Abstract 728

  • Knudsen LM, Hjorth M, Hippe E.
    Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group.
    Eur J Haematol 2000;65:175-81. PMID:11007053

  • Königsberg R et al.
    Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
    J Clin Oncol 2000;18:804-812. PMID:10673522

  • Kropff M et al.
    DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed multiple myeloma.
    Blood (ASH Annual Meeting Abstracts) 2007 110: Abstract 3599

  • Kumar S et al.
    Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
    Leukemia 2007;21:2035-2042. PMID:17581613

  • Kyle RA et al.
    Review of 1027 patients with newly diagnosed multiple myeloma.
    Mayo Clin Proc 2003;78:21-33. PMID:12528874

  • Lee CK et al.
    Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.
    Bone Marrow Transplant 2004;33:823-828. PMID:14767499

  • Lenhoff S et al.
    Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
    Br J Haematol 2006;133:389-396. PMID:16643445

  • Liebisch P et al.
    Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma.
    Genes Chromosomes Cancer 2005;42:78-81. PMID:15390182

  • Lokhorst HM et al.
    High-risk multiple myeloma treated with high-dose melphalan.
    J Clin Oncol 1992;1:47-51. PMID:1727925

  • McElwain TJ, Powles RL.
    High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
    Lancet 1983;8354:822-824. PMID:6137651

  • Lokhorst HM et al.
    Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
    Haematologica 2008;93:124-127. PMID:18166796

  • Mehta J et al.
    Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?
    Bone Marrow Transplant 1998;21:887-892. PMID:9613780

  • Moreau P et al.
    Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
    Blood 2002;99:731-735. PMID:11806971

  • Moreau P et al.
    Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
    Leukemia 2007;21:2020-2024. PMID:17625611

  • Morgan RJ Jr et al.
    Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma.
    Am J Hematol 1989;30:195-200. PMID:2929579

  • Myeloma Trialists’ Collaborative Group.
    Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.
    Br J Haematol 2001;113:1020-1034. PMID: 11442498

  • Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.
    J Clin Oncol 1998;16:3832-3842. PMID:9850028

  • Niesvizky R et al.
    BiRD (Biaxin(R)[clarithromycin]/Revlimid(R)[lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
    Blood 2008;111:1101-1109. PMID:17989313

  • Oakervee HE et al.
    PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
    Br J Haematol 2005;129:755-762. PMID:15953001

  • Orlowski RZ et al.
    Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
    J Clin Oncol 2002;20:4420-4427. PMID:12431963

  • Palumbo et al.
    A phase III study to compare melphalan, prednisone, lenalidomide (MPR) versus melphalan 200 mg/m2 and autologous transplantation (MEL200) in newly diagnosed multiple myeloma patients.
    Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 3573

  • Pasquali S et al.
    Renal histological lesions and clinical syndromes in multiple myeloma. Renal Immunopathology Group.
    Clin Nephrol 1987;27:222-228. PMID:3109793

  • Pasquini MC, Wang Z.
    Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2010.
    Available at: http://www.cibmtr.org (25.04.11)

  • Qazilbash MH et al.
    Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
    Cancer 2006;106:1084-1049. PMID:16456814

  • Rajkumar SV et al.
    Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
    Blood 2005;106:4050-4053. PMID:16118317

  • Rajkumar SV et al.
    Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
    J Clin Oncol 2006;24:431-436. PMID:16365178

  • Rajkumar SV et al.
    Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
    J Clin Oncol 2008;13:2171-2177. PMID:18362366

  • Reece DE et al.
    Autologous stem cell transplantation in multiple myeloma patients < 60 vs ≥ 60 years of age.
    Bone Marrow Transplant 2003;32:1135-1143. PMID:14647267

  • Richardson PG et al.
    Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
    Blood 2002;100:3063-3067. PMID:12384400

  • Sagaster V et al.
    Chromosomal abnormalities of young multiple myeloma patients (< 45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System.
    Eur J Haematol 2007;78:227-234. PMID:17253972

  • Sanders PW, Booker BB.
    Pathobiology of cast nephropathy from human Bence Jones proteins.
    J Clin Invest 1992;89:630-639. PMID:1737851

  • Sawyer JR et al.
    Cytogenetic findings in 200 patients with multiple myeloma.
    Cancer Genet Cytogenet 1995;82:41-49. PMID:7627933

  • SEER (Surveillance Epidemiology and End Results)
    SEER Stat Fact Sheets: Myeloma. http://seer.cancer.gov/statfacts/html/mulmy.html?statfacts_page=mulmy.html&x=11&y=18

  • Singhal S et al.
    Antitumor activity of thalidomide in refractory multiple myeloma.
    Engl J Med 1999;341:1565-1571. PMID:10564685

  • Sirohi B et al.
    The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
    Bone Marrow Transplant 2000;25:533-539. PMID:10713631

  • Stewart AK et al.
    Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.
    Clin Cancer Res 2004;10:8170-8176. PMID: 15623591

  • Straka C et al.
    The effects of induction chemotherapy and high-dose melphalan with tandem autologous transplantation in multiple myeloma: the prospective randomized DSMM 2 study.
    Blood (ASH Annual Meeting Abstracts) 2007 110: Abstract 446

  • Tricot G et al.
    Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy.
    Bone Marrow Transplant 1995;16:7-11. PMID:7581132

  • Turesson I et al.
    Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.
    Br J Haematol 1999;106:1005-1012. PMID:10520004

  • Wang M et al.
    Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
    Hematology 2007;12:235-239. PMID:17558699

  • Wu KL et al.
    Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Br J Haematol 2007;136:615-623. PMID:17223915

  • Zandecki M, Laï JL, Facon T.
    Multiple myeloma: almost all patients are cytogenetically abnormal.
    Br J Haematol 1996;94:217-227. PMID:8759879

  • Zucchelli P et al.
    Controlled plasma exchange trial in acute renal failure due to multiple myeloma.
    Kidney Int 1988;33:1175-1180. PMID:3043077

Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag [Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: